Turning Cancer Patients and Caregivers Into Informed Decision- Makers
Hi, my name is David Emerson, and I have been living with an incurable cancer called Multiple Myeloma since 1994. I started PeopleBeatingCancer.org because I believe that there is a problem with cancer care today. Cancer patients and caregivers are asked to make huge decisions about their health-- often while woefully uninformed, and under an extreme time crunch. How many of you are here because you were given 24 hours to approve your chemotherapy regimen?
Let me be clear: knowledge is power. The more you know, the better decisions you'll make for your care. Yes, I said YOU. You are in control. This website and the non-profit organization that supports it are dedicated to helping cancer survivors and caregivers become informed, educated decision-makers about their treatment. All information found on this site is evidence-based with the studies cited, and actionable-- you can get started using the protocols right away.
Welcome!
Check out our latest blog posts:
Selinexor (Xpovio) Approval-Multiple Myeloma-FDA?!
"Selinexor (Xpovio) approval & pricing highlights what’s wrong with our system (FDA),” Mayo MM specialist Dr. Vincent Rajkumar wrote..." I[...]
Senior Home Care Providers in Winnipeg
A lot of senior home care companies aim to assist the elderly in their daily tasks. This is also a[...]
Language of Oncology- What Multiple Myeloma Patients Need to Know-
"I don't want to call it dehumanization, but the language of (multiple myeloma) oncology that was instilled in us early[...]
Osteonecrosis of the Jaw- ONJ- Therapies for Multiple Myeloma Survivors
"The management of bisphosphonate-related osteonecrosis of the jaws (ONJ) for MM patients, is challenging and controversial. At present, there is[...]
Cancer Stem Cell Theory and Multiple Myeloma
"The bone marrow microenvironment provides to Multiple Myeloma CSCs self-renewal, survival and drug resistance thanks to the presence of normal and[...]
Clinical Trial Chemo Comparison for Multiple Myeloma-A to A
Comparing research for multiple myeloma (MM) therapies is frustrating at best, dangerous at worst. The goal for any/all MM patients[...]